Description
Nervismart (Pregabalin) 450 mg
Nervismart 450 mg is a pregabalin capsule product. Pregabalin is a prescription medicine used as an anticonvulsant and neuropathic pain treatment. The verified reference product information for pregabalin identifies oral capsule use and confirms the active ingredient as pregabalin.
Active Ingredient and Medicine Class
The active ingredient is pregabalin. It belongs to the class of anticonvulsant medicines and is also described as an alpha-2-delta ligand. It acts on voltage-gated calcium channel subunits in the nervous system.
Established Medical Uses
Official prescribing information for pregabalin includes treatment of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, neuropathic pain associated with spinal cord injury, fibromyalgia, and adjunctive therapy for partial-onset seizures.
How It Works
Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels and reduces the release of certain excitatory neurotransmitters. This is thought to help lessen abnormal nerve signaling that contributes to neuropathic pain and seizures.
Important Safety Information
Pregabalin should not be used in people with a known allergy to pregabalin or any product ingredient. Important precautions in official labeling include depression or suicidal thoughts, breathing problems, heart failure or other heart disease, swelling, kidney problems, and a history of substance misuse. Clinically significant interactions are noted with opioids, medicines for anxiety or insomnia, alcohol, and some other sedating drugs because these combinations can increase dizziness, sleepiness, and breathing problems. ACE inhibitors may increase the chance of swelling and hives.
Possible Side Effects
Common adverse effects include dizziness, sleepiness, blurred vision, dry mouth, weight gain, trouble concentrating, and swelling of the hands and feet. More serious reactions can include allergic reactions, severe breathing problems, vision changes, mood changes, and suicidal thoughts or behavior.
Scientific Evidence
Peer-reviewed evidence supports pregabalin as an effective option for several neuropathic pain conditions, with benefits shown in randomized trials and systematic reviews. Reviews also note that dizziness and somnolence are among the most frequent adverse effects.
Medical Information Notice
This page is an educational summary based on sources available at the time of review and does not replace the official patient leaflet or individual assessment by a qualified healthcare professional.
Medical Sources
- FDA, LYRICA (pregabalin) prescribing information.
- Sheena Derry et al., “Pregabalin for neuropathic pain in adults,” Cochrane Database of Systematic Reviews, 2019. PubMed
